When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
|
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Drug therapy in women: "Off-label use"?
    Thuermann, Petra A.
    PSYCHOPHARMAKOTHERAPIE, 2007, 14 (06): : 237 - 242
  • [42] TRENDS IN OFF-LABEL MIDODRINE USE IN MEDICAL AND SURGICAL CRITICALLY ILL PATIENTS
    Nasim, Faria
    Rizvi, Mahrukh
    Lin, Erica
    Trivedi, Vrinda
    Gajic, Ognjen
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 59 - 59
  • [43] Off-Label Drug Promotion and the Use of Disclaimers
    McKenney, Dina
    TEXAS LAW REVIEW, 2013, 92 (01) : 231 - 252
  • [44] Legal and Medical Aspects of Off-Label Medication Use. Point of View
    Tsygankova, Oksana V.
    Batluk, Tatiana I.
    Latyntseva, Ludmila D.
    Platonov, Dmitry Y.
    Akhmedzhanov, Nadir M.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (01) : 130 - 134
  • [45] United States medical practice summary - Innovative off-label medication use
    Ansani, Nicole
    Branch, Robert
    Fedutes-Henderson, Bethany
    Smitherman, Thomas
    Weber, Robert J.
    Skledar, Susan
    Zgheib, Nathalie
    Sirio, Carl
    AMERICAN JOURNAL OF MEDICAL QUALITY, 2006, 21 (04) : 246 - 254
  • [46] Medical Malpractice Litigation Due to Off-Label Use of Bone Morphogenetic Protein
    Weldon, Edward
    Razzouk, Jacob
    Bohen, Daniel
    Ramos, Omar
    Danisa, Olumide
    Cheng, Wayne
    SPINE, 2023, 48 (22) : 1575 - 1580
  • [47] Cardiac Intervention with Off-Label Use of Medical Devices in Congenital Heart Disease
    Kong, Young Hwa
    Song, Jin Young
    Huh, June
    Kang, I-Seok
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (16) : S31 - S31
  • [48] OFF-LABEL USE OF ONDANSETRON IN HOSPITALIZED MEDICAL PATIENTS: PREVALENCE, PATTERNS AND PREDICTORS
    Hartley, Sarah
    Kuhn, Latoya
    Valley, Staci
    Fallouh, Nabil
    Dussan, Kathleen
    Judd, Stephanie
    Murphy, Susan L.
    Saint, Sanjay
    Chopra, Vineet
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S130 - S131
  • [49] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [50] On-label and off-label drug use in the treatment of endometriosis
    Quaas, Alexander M.
    Weedin, Elizabeth A.
    Hansen, Karl R.
    FERTILITY AND STERILITY, 2015, 103 (03) : 612 - 625